Chembio Diagnostics, Inc. (NASDAQ: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the launch of its direct-to-consumer commercial channel for the third-party SCoV-2 Ag Detect Self-Test in the U.S. market. In addition, Chembio is expanding distribution of its SURE CHECK HIV Self-Test to consumers in Brazil and the United Kingdom by broadening the test kit’s existing Over-the-Counter (OTC) availability in national pharmacy chains.
Said CEO Richard Eberly, “We are excited to expand patient access to rapid, accurate and easy to use at home diagnostics across the United States, Brazil and the United Kingdom.
“This commercial expansion increases our addressable market and is intended to enable deeper penetration of the market as at home testing volumes continue to grow. This initiative directly aligns with our goal to focus on higher margin business in growing markets under our Global Competitiveness Program.”
Chembio is a leading diagnostics company focused on developing and commercializing point-of-care tests used to detect and diagnose infectious diseases, including sexually transmitted disease, insect vector and tropical disease.
CEMI shares opened Wednesday down a penny, or 1.6%, to 66 cents.
